Erratum: Case report: Sodium dichloroacetate (DCA) inhibition of the "Warburg Effect" in a human cancer patient: Complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP (Journal of Bioenergetics and Biomembranes (2012) DOI:10.1007/s10863-012-9496-2);Case report: Sodium dichloroacetate (DCA) inhibition of the "warburg Effect" in a human cancer patient: Complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP

Journal of Bioenergetics and Biomembranes

Volumn 45, Issue 3, 2013, Pages 307-315

  Strum, Stephen B ^a,b,c   Adalsteinsson, Örn ^d   Black, Richard R ^e   Segal, Dmitri ^f   Peress, Nancy L ^g   Waldenfels, James ^h  

^a International Strategic Cancer Alliance   (United States)

^b American Society of Clinical Oncology   (United States)

^c American Urological Association   (United States)

^d International Strategic Cancer Alliance   (United States)

^e Nuclear Medicine and PET Imaging   (United States)

^f Valley Radiology Consultants   (United States)

^g Life Extension Foundation   (United States)

^h Life Extension Foundation   (United States)

Author keywords

DCA; Dichloroacetate; Glycolysis; Metabolomics; NHL; non Hodgkin's lymphoma; PET; PET CT; Warburg

Indexed keywords

C REACTIVE PROTEIN; CAFFEINE; CIPROFLOXACIN; CLINDAMYCIN; CYCLOPHOSPHAMIDE; DICHLOROACETIC ACID; DOXORUBICIN; ISONIAZID; PREDNISONE; RIFAMPICIN; RITUXIMAB; THIAMINE; THIOCTIC ACID; VINCRISTINE SULFATE;

ABSENCE OF SIDE EFFECTS; ADULT; ANEMIA; ARTICLE; BILATERAL CANCER; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CARBONATED BEVERAGE; CASE REPORT; CERVICAL SPINE RADIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DOSE DENSIFICATION; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HEMATOCRIT; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HYPERMETABOLISM; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; MALE; MANDIBLE TUMOR; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NIGHT SWEAT; NODAL MARGINAL ZONE LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROTID GLAND TUMOR; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; SPLENOMEGALY; TEA; TREATMENT REFUSAL; TREATMENT RESPONSE; TUBERCULOSIS; TUMOR BIOPSY; TUMOR VOLUME; WEIGHT REDUCTION;

EID: 84878655372     PISSN: 0145479X     EISSN: 15736881     Source Type: Journal    
DOI: 10.1007/s10863-013-9516-x     Document Type: Erratum

References (33)

1. Berendzen K, Theriaque DW, Shuster J, Stacpoole PW (2006) Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. Mitochondrion 6:126-135
2. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R et al (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37-51
3. Bui T, Thompson CB (2006) Cancer's sweet tooth. Cancer Cell 9:419-420
4. Bustamante E, Pedersen PL (1977) High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A 74:3735-3739
5. Bustamante E, Morris HP, Pedersen PL (1981) Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 256:8699-8704
6. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S et al (2008) Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 68:1223-1231
7. Chen Z, Lu W, Garcia-Prieto C, Huang P (2007) The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39:267-274
8. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230-233
9. Constantin-Teodosiu D, Simpson EJ, Greenhaff PL (1999) The importance of pyruvate availability to PDC activation and anaplerosis in human skeletal muscle. Am J Physiol 276:E472-E478
10. Fang JS, Gillies RD, Gatenby RA (2008) Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 18:330-337
11. Gatenby RA, Gawlinski ET (2003) The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 63:3847-3854
12. Heerdt BG, Houston MA, Augenlicht LH (2005) The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res 65:9861-9867
13. Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M et al (2002) Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 43:173-180
14. Kuroda Y, Ito M, Toshima K, Takeda E, Naito E, Hwang TJ et al (1986) Treatment of chronic congenital lactic acidosis by oral administration of dichloroacetate. J Inherit Metab Dis 9:244-252
15. Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG (2010) Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br J Cancer 102:1746-1752
16. Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29:339-343
17. Mathupala SP, Rempel A, Pedersen PL (2001) Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276:43407-43412
18. Michelakis ED, Webster L, Mackey JR (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99:989-994
19. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E et al (2010) Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2:31ra34
20. Pan JG, Mak TW (2007) Metabolic targeting as an anticancer strategy: dawn of a new era? Sci STKE 2007:14
21. Remillard CV, Yuan JX (2004) Activation of K+ channels: an essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol 286:L49-L67
22. Stacpoole PW, Barnes CL, Hurbanis MD, Cannon SL, Kerr DS (1997) Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 77:535-541
23. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM et al (2006) Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 117:1519-1531
24. Stacpoole PW, Gilbert LR, Neiberger RE, Carney PR, Valenstein E, Theriaque DW et al (2008) Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics 121:e1223-e1228
25. Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC (2010) Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 120:253-260
26. Tong J, Xie G, He J, Li J, Pan F, Liang H (2011) Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol 2011:740564
27. Vander Heiden MG (2010) Targeting cell metabolism in cancer patients. Sci Transl Med 2:31ed31
28. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-150S
29. Wang Z (2004) Roles of K+ channels in regulating tumour cell proliferation and apoptosis. Pflugers Arch 448:274-286
30. Warburg O (1956a) On respiratory impairment in cancer cells. Science 124:269-270
31. Warburg O (1956b) On the origin of cancer cells. Science 123:309-314
32. Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519-530
33. Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I (2008) Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 109:394-402